Floatz logo

Zanzalintinib

Pancreatic Neuroendocrine Tumor

ExelixisSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Pancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Oxodotreotide
University of Chicago
Phase 4BBB
Everolimus
Exelixis
Phase 4BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 2/3BB
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-
RayzeBio, Inc.
Phase 3BB
Capecitabine
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BB

View all 49 →

Same molecule, other indications

Zanzalintinib is also rated in:

renal cell carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
hepatocellular carcinomaActive
BB
Indicative · Phase 3
65 / 100
View asset →
nonpapillary renal cell carcinomaActive
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →